Form 483

Novo Nordisk Inc. Form 483, 2025-02-07

FDA issued a Form 483 to Novo Nordisk Inc. on 2025-02-07 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Novo Nordisk Inc. · Plainsboro, United States · Issued February 7, 2025

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

7 Feb 2025
21 CFR 314.80(b)

Failure to develop written procedures

Cited by Tyanna N Hadley, Mayar M Mussa

7 Feb 2025
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Tyanna N Hadley, Mayar M Mussa

7 Feb 2025
21 CFR 314.80(c)(1)(ii)

Failure to investigate serious, unexpected events

Cited by Tyanna N Hadley, Mayar M Mussa

7 Feb 2025
21 CFR 314.80(c)(2)(ii)(B)

Late submission of an ICSR

Cited by Tyanna N Hadley, Mayar M Mussa

Inspected site

NNNovo Nordisk Inc.Plainsboro, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 314.80(b)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(ii)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(2)(ii)(B)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere